ABCDEFGHIJKLMNO
1
TYPEIDSTATUSTITLEPHASEPATIENTIDH STATUSSPONSORCONTACTEMAILNOTESFIND ME CURE LINKCLINICALTRIALS GOV LINKPUBLISHED REFERENCES
2
ComboNCT05009992RECRUITINGCombination Therapy for the Treatment of Diffuse Midline GliomasPhase 2BothAnyUniversity of California, San FranciscoKelly HitchnerPNOC022@ucsf.eduCountries: Australia; Israel; Netherlands; New Zealand; Switzerland; United States.https://www.findmecure.com/clinicaltrials/show/nct05009992https://clinicaltrials.gov/study/NCT05009992https://pmc.ncbi.nlm.nih.gov/articles/PMC11066905/
3
ComboNCT05096481RECRUITINGPEP-CMV Vaccine Targeting CMV Antigen to Treat Newly Diagnosed Pediatric HGG and DIPG and Recurrent MedulloblastomaPhase 2BothAnyNationwide Children's HospitalKelsey H Troyer, PhDkelsey.troyer@nationwidechildrens.orghttps://www.findmecure.com/clinicaltrials/show/nct05096481https://clinicaltrials.gov/study/NCT05096481https://pubmed.ncbi.nlm.nih.gov/40506525/
4
ComboNCT05345002RECRUITINGAll-Trans Retinoic Acid (ATRA) Plus PD-1 Inhibition in Recurrent IDH-Mutant GliomaPhase 2BothMutantStephen Bagley, MD, MSCEStephen Bagley, MD MSCEPMCancerResearch@pennmedicine.upenn.eduhttps://www.findmecure.com/clinicaltrials/show/nct05345002https://clinicaltrials.gov/study/NCT05345002https://pubmed.ncbi.nlm.nih.gov/38645178/
5
ComboNCT05864534RECRUITINGPhase 2a Immune Modulation With Ultrasound for Newly Diagnosed GlioblastomaPhase 2BothAnyNorthwestern UniversityNeurological Surgerybraintumortrials@nm.orghttps://www.findmecure.com/clinicaltrials/show/nct05864534https://clinicaltrials.gov/study/NCT05864534https://www.nature.com/articles/s41467-024-48326-w
6
ComboNCT06061809RECRUITINGN-803 and PD-L1 t-haNK Combined With Bevacizumab for Recurrent or Progressive GlioblastomaPhase 2BothWild TypeImmunityBio, Inc.Raymond AtiataRaymond.Atiata@immunitybio.comhttps://www.findmecure.com/clinicaltrials/show/nct06061809https://clinicaltrials.gov/study/NCT06061809https://academic.oup.com/neuro-oncology/article/27/Supplement_5/v119/8318166
7
ComboNCT06805305RECRUITINGDOC1021 Dendritic Cell Immunotherapy for Treatment of Newly Diagnosed Adult Glioblastoma (GBM)Phase 2BothAnyDiakonos Oncology CorporationJames SchohnJames.Schohn@bannerhealth.comhttps://www.findmecure.com/clinicaltrials/show/nct06805305https://clinicaltrials.gov/study/NCT06805305https://www.medrxiv.org/content/10.64898/2026.03.28.26349013v1
8
ComboNCT06816927RECRUITINGTrial of Glioblastoma Immunotherapy Advancement With Nivolumab and RelatlimabPhase 2BothAnyDuke UniversityMustafa Khasrawmustafa.khasraw@duke.eduhttps://www.findmecure.com/clinicaltrials/show/nct06816927https://clinicaltrials.gov/study/NCT06816927https://www.nature.com/articles/s41591-025-03512-1
9
ComboNCT05463848RECRUITINGSurgical Pembro +/​- Olaparib w TMZ for rGBMPhase 2RecurrentAnyL. Nicolas Gonzalez Castro, MD, PhDL. Nicolas Gonzalez Castrolgonzalez-castro@partners.orghttps://findmecure.com/clinicaltrials/show/nct05463848https://clinicaltrials.gov/study/NCT05463848https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11075475/
10
ComboNCT05465954RECRUITINGEfineptakin Alfa and Pembrolizumab for the Treatment of Recurrent GlioblastomaPhase 2RecurrentAnyMayo ClinicClinical Trials Referral Officemayocliniccancerstudies@mayo.eduhttps://findmecure.com/clinicaltrials/show/nct05465954https://clinicaltrials.gov/study/NCT05465954https://ascopubs.org/doi/10.1200/JCO.2023.41.16_suppl.TPS2085
11
ComboNCT06160206RECRUITINGRetifanlimab with Bevacizumab and Hypofractionated Radiotherapy for the Treatment of Recurrent GlioblastomaPhase 2RecurrentAnyAcademic and Community Cancer Research UnitedInbox Mayo Clinic Cancer StudiesMAYOCLINICCANCERSTUDIES@mayo.eduhttps://www.findmecure.com/clinicaltrials/show/nct06160206https://clinicaltrials.gov/study/NCT06160206https://www.asco.org/abstracts-presentations/201191/abstract
12
ComboNCT06177964RECRUITINGLerapolturev (PVSRIPO) in GBMPhase 2RecurrentAnyDarell BignerMadison Shoaf, MDdukebrain1@dm.duke.eduhttps://www.findmecure.com/clinicaltrials/show/nct06177964https://clinicaltrials.gov/study/NCT06177964https://pubmed.ncbi.nlm.nih.gov/29943666/
13
ComboNCT06558214RECRUITINGOPTIMUS PRIME: Safety and Feasibility of OPTune GIO® Integrated With MRI-gUided Laser Ablation Surgery and Pembrolizumab for Recurrent GlIoblastoMa, A randomizEd TrialPhase 2RecurrentWild TypeUniversity of FloridaVictoria Hopevictoria.hope@neurosurgery.ufl.eduhttps://www.findmecure.com/clinicaltrials/show/nct06558214https://clinicaltrials.gov/study/NCT06558214https://www.nature.com/articles/s41467-026-69522-w
14
ComboNCT07301268RECRUITINGGI-102 Alone or With Pembrolizumab Before Surgery for Treatment of Recurrent or Progressive IDH Wild Type Glioblastoma and IDH Mutated Grade 4 AstrocytomaPhase 2RecurrentWild TypeMayo ClinicClinical Trials Referral Officemayocliniccancerstudies@mayo.eduhttps://www.findmecure.com/clinicaltrials/show/nct07301268https://clinicaltrials.gov/study/NCT07301268https://ascopubs.org/doi/10.1200/JCO.2024.42.16_suppl.2598
15
ComboNCT05734560RECRUITINGD2C7-IT and 2141-V11 in Newly Diagnosed GBM PatientsPhase 1/2Newly DiagnosedAnyDarell BignerDaniel Landi, MDdukebrain1@dm.duke.eduhttps://findmecure.com/clinicaltrials/show/nct05734560https://clinicaltrials.gov/study/NCT05734560https://ascopubs.org/doi/10.1200/JCO.2022.40.16_suppl.e14015
16
ComboNCT05084430RECRUITINGStudy of Pembrolizumab and M032Phase 1/2BothAnyUniversity of Alabama at BirminghamJames Markert, MDjmarkert@uabmc.eduhttps://findmecure.com/clinicaltrials/show/nct05084430https://clinicaltrials.gov/study/NCT05084430https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4932657/
17
ComboNCT06504381RECRUITINGDB107-RRV, DB107-FC, and Radiation Therapy With or Without Temozolomide (TMZ) for High Grade GliomaPhase 1/2BothWild TypeUniversity of California, San FranciscoStephanie Lewis, RNstephanie.lewis2@ucsf.eduhttps://www.findmecure.com/clinicaltrials/show/nct06504381https://clinicaltrials.gov/study/NCT06504381https://pmc.ncbi.nlm.nih.gov/articles/PMC6120351/
18
ComboNCT06712875RECRUITINGMAPK Inhibition Combined With Anti-PD1 Therapy for BRAF-altered Pediatric GliomasPhase 1/2BothAnyAnn & Robert H Lurie Children's Hospital of ChicagoMonica Newmarkmnewmark@luriechildrens.orghttps://www.findmecure.com/clinicaltrials/show/nct06712875https://clinicaltrials.gov/study/NCT06712875https://pmc.ncbi.nlm.nih.gov/articles/PMC8168157/
19
ComboNCT07346144RECRUITINGStudy of an AAV Mediated Dual-Payload Gene Therapy in Patients With High Grade GliomaPhase 1/2BothAnyTrogenix ltdProject ManagementContact@trogenix.comCountries: United Kingdom; United States.https://www.findmecure.com/clinicaltrials/show/nct07346144https://clinicaltrials.gov/study/NCT07346144https://www.nature.com/articles/s41586-026-10329-6
20
ComboNCT03596086RECRUITINGHSV-tk + Valacyclovir + SBRT + Chemotherapy for Recurrent GBMPhase 1/2RecurrentAnyDavid Baskin MDDavid S Baskin, MDDBaskin@houstonmethodist.orghttps://findmecure.com/clinicaltrials/show/nct03596086https://clinicaltrials.gov/study/NCT03596086https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9998375/
21
ComboNCT04977375RECRUITINGTrial of Anti-PD-1 Immunotherapy and Stereotactic Radiation in Patients With Recurrent GlioblastomaPhase 1/2RecurrentAnyChirag G. PatilClinical Trial Recruitment Navigatorcancer.trial.info@cshs.orghttps://findmecure.com/clinicaltrials/show/nct04977375https://clinicaltrials.gov/study/NCT04977375https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11075475/
22
ComboNCT05039281RECRUITINGAtezolizumab and Cabozantinib for the Treatment of Recurrent GlioblastomaPhase 1/2RecurrentAnyM.D. Anderson Cancer CenterEva Gachimovaegachimova@mdanderson.orghttps://findmecure.com/clinicaltrials/show/nct05039281https://clinicaltrials.gov/study/NCT05039281
23
ComboNCT05423210RECRUITINGAtezolizumab and Pre-Surgical Brain Radiation Therapy for Glioblastoma MultiformePhase 1Newly DiagnosedAnyStony Brook UniversityCatherine Izzo, MScatherine.izzo@stonybrookmedicine.eduhttps://findmecure.com/clinicaltrials/show/nct05423210https://clinicaltrials.gov/study/NCT05423210
24
ComboNCT04099797RECRUITINGC7R-GD2.CAR T Cells for Patients With GD2-expressing Brain Tumors (GAIL-B)Phase 1BothAnyBaylor College of MedicineJasia Mahdi, MDJasia.Mahdi@bcm.eduhttps://ascopubs.org/doi/10.1200/JCO.2025.43.16_suppl.2018https://clinicaltrials.gov/study/NCT04099797https://pubmed.ncbi.nlm.nih.gov/38771986/
25
ComboNCT04196413RECRUITINGGD2 CAR T Cells in Diffuse Intrinsic Pontine Gliomas (DIPG) & Spinal Diffuse Midline Glioma(DMG)Phase 1BothAnyStanford UniversityAshley Jacobs, RN, BSNgd2cart@stanfordchildrens.orghttps://www.findmecure.com/ClinicalTrials/Show/NCT04196413https://clinicaltrials.gov/study/NCT04196413https://www.nature.com/articles/s41586-024-08171-9
26
ComboNCT04943848RECRUITINGrHSC-DIPGVax Plus Checkpoint Blockade for the Treatment of Newly Diagnosed DIPG and DMGPhase 1BothAnyAnn & Robert H Lurie Children's Hospital of ChicagoMonica Newmark, BS, RNMNewmark@luriechildrens.orghttps://www.findmecure.com/clinicaltrials/show/nct04943848https://clinicaltrials.gov/study/NCT04943848https://pmc.ncbi.nlm.nih.gov/articles/PMC11183657/
27
ComboNCT05083754RECRUITINGCarmustine Wafer in Combination With Retifanlimab and Radiation With/Without Temozolomide in Subjects With GlioblastomaPhase 1BothAnySidney Kimmel Comprehensive Cancer Center at Johns HopkinsLawrence Kleinberg, MDkleinla@jhmi.eduhttps://www.findmecure.com/clinicaltrials/show/nct05083754https://clinicaltrials.gov/study/NCT05083754
28
ComboNCT05106296RECRUITINGChemo-immunotherapy Using Ibrutinib Plus Indoximod for Patients With Pediatric Brain CancerPhase 1BothAnyTheodore S. JohnsonTheodore S. Johnson, MD, PhDthjohnson@augusta.eduhttps://www.findmecure.com/clinicaltrials/show/nct05106296https://clinicaltrials.gov/study/NCT05106296https://pmc.ncbi.nlm.nih.gov/articles/PMC10836763/
29
ComboNCT06186401RECRUITINGAnti-EGFRvIII synNotch Receptor Induced Anti-EphA2/IL-13Ralpha2 CAR (E-SYNC) T CellsPhase 1BothAnyHideho Okada, MD, PhDNeuro-Oncology New Patient CoordinatorNeuroOncNewPatientCoord@ucsf.eduhttps://www.findmecure.com/clinicaltrials/show/nct06186401https://clinicaltrials.gov/study/NCT06186401https://pubmed.ncbi.nlm.nih.gov/33910979/
30
ComboNCT06193759RECRUITINGImmunotherapy for Malignant Pediatric Brain Tumors Employing Adoptive Cellular Therapy (IMPACT)Phase 1BothAnyChildren's National Research InstituteBrian Rood, MDBROOD@childrensnational.orghttps://www.findmecure.com/clinicaltrials/show/nct06193759https://clinicaltrials.gov/study/NCT06193759https://www.findmecure.com/clinicaltrials/show/nct06193759
31
ComboNCT07343986RECRUITINGStudy of Low-Intensity Focused Ultrasound in Combination With Immunotherapy in Newly Diagnosed Unmethylated GlioblastomaPhase 1BothWild TypeUniversity of VirginiaBettina Wagner, B.A.WXQ9ET@uvahealth.orghttps://www.findmecure.com/clinicaltrials/show/nct07343986https://clinicaltrials.gov/study/NCT07343986https://pmc.ncbi.nlm.nih.gov/articles/PMC10834565/
32
ComboNCT03988283RECRUITINGNeoepitope-based Personalized DNA Vaccine Approach in Pediatric Patients With Recurrent Central Nervous System TumorsPhase 1RecurrentAnyWashington University School of MedicineMichael A Huang, M.D.huangm@wustl.eduhttps://www.findmecure.com/clinicaltrials/show/nct03988283https://clinicaltrials.gov/study/NCT03988283https://pmc.ncbi.nlm.nih.gov/articles/PMC8059244/
33
ComboNCT04510051RECRUITINGCAR T Cells After Lymphodepletion for the Treatment of IL13Rα2 Positive Recurrent or Refractory Brain Tumors in ChildrenPhase 1RecurrentAnyCity of Hope Medical CenterLeo D WangPediatricTrials@coh.orghttps://www.findmecure.com/clinicaltrials/show/nct04510051https://clinicaltrials.gov/study/NCT04510051https://pmc.ncbi.nlm.nih.gov/articles/PMC10635314/
34
ComboNCT04547777RECRUITINGPhase 1 Trial of D2C7-IT in Combination With 2141-V11 for Recurrent Malignant GliomaPhase 1RecurrentAnyDarell BignerAnnick Desjardins, MD. FRCPCdukebrain1@dm.duke.eduhttps://findmecure.com/clinicaltrials/show/nct04547777https://clinicaltrials.gov/study/NCT04547777https://ascopubs.org/doi/10.1200/JCO.2022.40.16_suppl.e14015
35
ComboNCT05686798RECRUITINGAdenovirus Mediated Suicide Gene Therapy With Radiotherapy in Progressive AstrocytomaPhase 1RecurrentAnyHenry Ford Health SystemTobias Walbert, MD, PhDtwalber1@hfhs.orgThis is a 20 year old approach first pursued in prostate cancerhttps://findmecure.com/clinicaltrials/show/nct05686798https://clinicaltrials.gov/study/NCT05686798https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4127140/
36
ComboNCT06815029RECRUITINGIntracranial Genetically Modified Immune Cells (TGFβR2KO/IL13Rα2 CAR T-Cells) for the Treatment of Recurrent or Progressive Glioblastoma or Grade 3 or 4 IDH-Mutant AstrocytomaPhase 1RecurrentMutantCity of Hope Medical CenterBehnam Badiebbadie@coh.orghttps://www.findmecure.com/clinicaltrials/show/nct06815029https://clinicaltrials.gov/study/NCT06815029https://pubmed.ncbi.nlm.nih.gov/38454126/
37
ComboNCT06840886RECRUITINGA Study of PHST001 in Advanced Solid TumorsPhase 1RecurrentAnyPheast TherapeuticsAndrew Ferguson/VP Clinical Development, PhDmedical@pheast.comCD24 antibody, macrophage checkpoint inhibitorhttps://www.findmecure.com/clinicaltrials/show/nct06840886https://clinicaltrials.gov/study/NCT06840886https://jitc.bmj.com/content/12/Suppl_2/A578
38
ComboNCT06914479RECRUITINGVirus-Based Gene Therapy (AdV-HSV1-TK and AdV-Flt3L) in Combination With Valacyclovir for the Treatment of Pediatric and Young Adult Patients With Resectable, Recurrent Primary Malignant Brain TumorsPhase 1RecurrentAnyUniversity of Michigan Rogel Cancer CenterCancer AnswerLineCancerAnswerLine@med.umich.eduhttps://www.findmecure.com/clinicaltrials/show/nct06914479https://clinicaltrials.gov/study/NCT06914479https://pubmed.ncbi.nlm.nih.gov/37657463/
39
ComboNCT06519682RECRUITINGA Pilot Study Investigating Upfront Adaptive Immunotherapy Approach in Children, Adolescent and Young Adult (CAYA) Patients With Replication-Repair Deficient (RRD) High-Grade Gliomas (HGG)​RecurrentAnyDaniel MorgensternNirav Thacker, MDNthacker@cheo.on.caCountries: Canada.https://www.findmecure.com/clinicaltrials/show/nct06519682https://clinicaltrials.gov/study/NCT06519682https://pubmed.ncbi.nlm.nih.gov/37126021/
40
MonoNCT02358187RECRUITINGA Vaccine Trial for Low Grade GliomasPhase 2RecurrentAnyJames FelkerJames Felker, MDsharon.dibridge@chp.eduhttps://www.findmecure.com/clinicaltrials/show/nct02358187https://clinicaltrials.gov/study/NCT02358187https://pmc.ncbi.nlm.nih.gov/articles/PMC4933485/
41
MonoNCT03603405RECRUITINGHSV-tk and XRT and Chemotherapy for Newly Diagnosed GBMPhase 1/2BothAnyThe Methodist Hospital Research InstituteDavid S. Baskin, MDDBaskin@houstonmethodist.orghttps://www.findmecure.com/clinicaltrials/show/nct03603405https://clinicaltrials.gov/study/NCT03603405https://pmc.ncbi.nlm.nih.gov/articles/PMC4638898/
42
MonoNCT04573140RECRUITINGA Study of RNA-lipid Particle (RNA-LP) Vaccines for Newly Diagnosed Pediatric High-Grade Gliomas (pHGG) and Adult Glioblastoma (GBM) (PNOC020)Phase 1Newly DiagnosedAnyUniversity of FloridaMarcia Hodikmarcia.hodik@neurosurgery.ufl.eduMust be MGMT unmethylatedhttps://findmecure.com/clinicaltrials/show/nct04573140https://clinicaltrials.gov/study/NCT04573140https://www.sciencedirect.com/science/article/abs/pii/S0092867424003982?via%3Dihub
43
MonoNCT05366179RECRUITINGAutologous CAR-T Cells Targeting B7-H3 in Recurrent or Refractory GBM CAR.B7-H3TcPhase 1BothAnyUNC Lineberger Comprehensive Cancer CenterCatherine ChengUNCImmunotherapy@med.unc.eduhttps://www.findmecure.com/clinicaltrials/show/nct05366179https://clinicaltrials.gov/study/NCT05366179https://pubmed.ncbi.nlm.nih.gov/31466914/
44
MonoNCT05660369RECRUITINGCARv3-TEAM-E T Cells in GlioblastomaPhase 1BothAnyMarcela V. Maus, M.D.,Ph.D.William Curry, MDcarteamingbm@mgb.orghttps://www.findmecure.com/clinicaltrials/show/nct05660369https://clinicaltrials.gov/study/NCT05660369https://www.nejm.org/doi/full/10.1056/NEJMoa2314390
45
MonoNCT06305910RECRUITINGCD200AR-L and Allogeneic Tumor Lysate Vaccine Immunotherapy for Recurrent HGG and Newly Diagnosed DMG/DIPG in Children and Young AdultsPhase 1BothAnyOX2 TherapeuticsAnne Bendel, MDanne.bendel@childrensmn.orghttps://www.findmecure.com/clinicaltrials/show/nct06305910https://clinicaltrials.gov/study/NCT06305910https://pubmed.ncbi.nlm.nih.gov/34882581/
46
MonoNCT06917885RECRUITINGCUE-102 in Recurrent GlioblastomaPhase 1BothAnyDavid Reardon, MDDavid Reardon, MDdavid_reardon@dfci.harvard.eduhttps://pmc.ncbi.nlm.nih.gov/articles/PMC11066905/https://clinicaltrials.gov/study/NCT06917885https://jitc.bmj.com/content/11/Suppl_1/A846
47
MonoNCT06973096RECRUITINGCART-EGFR-IL13Ra2 in Newly Diagnosed GBM Following Initial RadiotherapyPhase 1BothWild TypeUniversity of PennsylvaniaAbramson Cancer Center Clinical Trials ServicePMCancerResearch@pennmedicine.upenn.eduhttps://www.findmecure.com/clinicaltrials/show/nct06973096https://clinicaltrials.gov/study/NCT06973096https://pubmed.ncbi.nlm.nih.gov/40451950/
48
MonoNCT03896568RECRUITINGMSC-DNX-2401 in Treating Patients With Recurrent High-Grade GliomaPhase 1RecurrentAnyM.D. Anderson Cancer CenterFrederick Langflang@mdanderson.orghttps://findmecure.com/clinicaltrials/show/nct03896568https://clinicaltrials.gov/study/NCT03896568https://thejns.org/view/journals/j-neurosurg/136/3/article-p757.xml
49
MonoNCT04323046RECRUITINGImmunotherapy Before and After Surgery for Treatment of Recurrent or Progressive High Grade Glioma in Children and Young Adults Phase 1RecurrentAnySabine Mueller, MD, PhD (UCSF)Jannerfer AnPNOC019@ucsf.eduFor children and young adults under age 25 only. Drug is nivolumab.https://findmecure.com/clinicaltrials/show/nct04323046https://clinicaltrials.gov/study/NCT04323046https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10232854/
50
MonoNCT04991870RECRUITINGEngineered NK Cells Containing Deleted TGF-BetaR2 and NR3C1 for the Treatment of Recurrent GlioblastomaPhase 1RecurrentAnyM.D. Anderson Cancer CenterShiao-Pei Weathers, MDsweathers@mdanderson.orghttps://findmecure.com/clinicaltrials/show/nct04991870https://clinicaltrials.gov/study/NCT04991870https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8279586/
51
MonoNCT05474378RECRUITINGB7-H3 Chimeric Antigen Receptor T Cells (B7-H3CART) in Recurrent Glioblastoma MultiformePhase 1RecurrentWild TypeStanford UniversityKelly Tannerketanner@stanford.eduhttps://www.findmecure.com/clinicaltrials/show/nct05474378https://clinicaltrials.gov/study/NCT05474378https://ascopubs.org/doi/10.1200/JCO.2025.43.16_suppl.2018
52
MonoNCT06964737RECRUITINGAnti-GARP Chimeric Antigen Receptor T Cell Therapy for the Treatment of Recurrent Grade III or IV GliomasPhase 1RecurrentAnyOhio State University Comprehensive Cancer CenterOhio State University Comprehensive Cancer CenterOSUCCCclinicaltrials@osumc.eduhttps://www.findmecure.com/clinicaltrials/show/nct06964737https://clinicaltrials.gov/study/NCT06964737https://pubmed.ncbi.nlm.nih.gov/40873341/
53
MonoNCT07209241RECRUITINGDifferent Approaches for CART-EGFR-IL13Ra2 Dosing in Recurrent GBMPhase 1RecurrentWild TypeUniversity of PennsylvaniaAbramson Cancer Center Clinical Trials, MD, MSCEPMCancerResearch@pennmedicine.upenn.eduhttps://www.findmecure.com/clinicaltrials/show/nct07209241https://clinicaltrials.gov/study/NCT07209241https://pmc.ncbi.nlm.nih.gov/articles/PMC12715680/
54
ComboNCT05053880UNKNOWNA Study to Evaluate Safety and Efficacy of ACT001 and Anti-PD-1 in Patients With Surgically Accessible Recurrent Glioblastoma MultiformePhase 1/2RecurrentAnyAccendatech USA Inc.C3 Research AssociatesACT001-US-001@c3-research.comExperimental drug is not an immunotherapy. Will be randomized to one of two groups: pembrolizumab alone or pembrolizumab plus ACT001https://findmecure.com/clinicaltrials/show/nct05053880https://clinicaltrials.gov/study/NCT05053880https://ascopubs.org/doi/10.1200/JCO.2021.39.15_suppl.2037
55
ComboNCT05700955UNKNOWNNeoadjuvant Chemoimmunotherapy in Recurrent GlioblastomaPhase 1RecurrentAnyUniversity of LouisvilleDonald Miller, MDDonald.miller@louisville.eduCombination is pembrolizumab and temozolomidehttps://findmecure.com/clinicaltrials/show/nct05700955https://clinicaltrials.gov/study/NCT05700955https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11075475/
56
MonoNCT05095441UNKNOWNA Clinical Study of Intratumoral MVR-C5252 (C5252) in Patients With Recurrent or Progressive GlioblastomaPhase 1RecurrentAnyImmVira Pharma Co. LtdRandy Jensen, MDclinicaltrials@immviragroup.com https://findmecure.com/clinicaltrials/show/nct05095441https://clinicaltrials.gov/study/NCT05095441https://www.sciencedirect.com/science/article/pii/S2950329924000419
57
ComboNCT04485949ACTIVE_NOT_RECRUITINGA Phase 2b Clinical Study With a Combination Immunotherapy in Newly Diagnosed Patients With GlioblastomaPhase 2Newly DiagnosedAnyImvaxMadhavi Diwanjim.diwanji@imvax.comRandomized to 1 of 2 groups: Placebo plus SOC vs IGV-001 plus SOC.https://findmecure.com/clinicaltrials/show/nct04485949https://clinicaltrials.gov/study/NCT04485949https://pubmed.ncbi.nlm.nih.gov/38060340/
58
ComboNCT05685004ACTIVE_NOT_RECRUITINGStudy of Neoantigen-specific Adoptive T Cell Therapy for Newly Diagnosed MGMT Negative Glioblastoma Multiforme (GBM)Phase 2Newly DiagnosedAnyTVAX BiomedicalJean Aguiarinfo@tvaxbiomedical.comMust be MGMT unmethylated. Randomized to 1 of 2 groups: Placebo plus SOC vs TVI-Brain-1 plus SOC.https://findmecure.com/clinicaltrials/show/nct05685004https://clinicaltrials.gov/study/NCT05685004https://pubmed.ncbi.nlm.nih.gov/16817692/
59
ComboNCT04729959ACTIVE_NOT_RECRUITINGTesting the Addition of the Immune Therapy Drugs, Tocilizumab and Atezolizumab, to Radiation Therapy for Recurrent GlioblastomaPhase 2RecurrentAnyNational Cancer Institute (NCI)NCI NOB Referral Groupncinobreferrals@mail.nih.govTrial will study the combination of atezolizumab (anti-PD-L1) and fractionated stereotactic radiation therapy (FSRT), with versus (vs.) without tocilizumab (anti-IL6R)https://findmecure.com/clinicaltrials/show/nct04729959https://clinicaltrials.gov/study/NCT04729959https://www.rtog.org/News/A-Safety-Run-in-and-Phase-II-Study-Evaluating-the-Efficacy
60
ComboNCT05664243ACTIVE_NOT_RECRUITINGA Phase 1b /​ 2 Drug Resistant Immunotherapy With Activated, Gene Modified Allogeneic or Autologous γδ T Cells (DeltEx) in Combination With Maintenance Temozolomide in Subjects With Recurrent or Newly Diagnosed GlioblastomaPhase 1/2BothAnyIn8bio Inc.Trishna Goswami, MDINB-400@in8bio.comINB-400https://findmecure.com/clinicaltrials/show/nct05664243https://clinicaltrials.gov/study/NCT05664243https://ascopubs.org/doi/10.1200/JCO.2023.41.16_suppl.2007https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10766231/
61
ComboNCT02287428ACTIVE_NOT_RECRUITINGPersonalized NeoAntigen Cancer Vaccine w RT Plus Pembrolizumab for Patients With Newly Diagnosed GBMPhase 1Newly DiagnosedAnyDana-Farber Cancer InstituteDavid A Reardon, MDdavid_reardon@dfci.harvard.eduhttps://findmecure.com/clinicaltrials/show/nct02287428https://clinicaltrials.gov/study/NCT02287428https://www.nature.com/articles/s41586-018-0792-9
62
ComboNCT04003649ACTIVE_NOT_RECRUITINGIL13Ra2-CAR T Cells With or Without Nivolumab and Ipilimumab in Treating Patients With GBMPhase 1RecurrentAnyCity of Hope Medical CenterBehnam Badiebbadie@coh.orgRandomized to 1 of 3 cohorts: 1) IL13Ra2-CAR T only, 2) CAR-T + nivolumab, 3) CAR-T + nivolumab + ipilimumabhttps://findmecure.com/clinicaltrials/show/nct04003649https://clinicaltrials.gov/study/NCT04003649https://www.frontiersin.org/journals/immunology/articles/10.3389/fimmu.2021.715000/full
63
ComboNCT04201873ACTIVE_NOT_RECRUITINGPembrolizumab and a Vaccine (ATL-DC) for the Treatment of Surgically Accessible Recurrent GlioblastomaPhase 1RecurrentAnyJonsson Comprehensive Cancer CenterQuan Li, Ph.D.quanli@mednet.ucla.eduRandomized to 1 of 2 groups ATL-DC (with or without pembrolizumab)https://findmecure.com/clinicaltrials/show/nct04201873https://clinicaltrials.gov/study/NCT04201873https://jamanetwork.com/journals/jamaoncology/fullarticle/2798847
64
ComboNCT04656535ACTIVE_NOT_RECRUITINGAB154 Combined With AB122 for Recurrent GlioblastomaPhase 1RecurrentAnyYale UniversityTara McPartlandtara.mcpartland@yale.eduTwo cohorts:
A) AB154 + AB122

B)
B1: AB154 single agent + placebo
B2: AB122 single agent + placebo
B3: AB154 +AB122
B4: Two placebo infusions		https://findmecure.com/clinicaltrials/show/nct04656535https://clinicaltrials.gov/study/NCT04656535https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10030909/
65
MonoNCT03718767ACTIVE_NOT_RECRUITINGNivolumab in Patients With IDH-Mutant Gliomas With and Without Hypermutator PhenotypePhase 2RecurrentMutantNational Cancer Institute (NCI)NCI NOB Referral Groupncinobreferrals@mail.nih.govhttps://findmecure.com/clinicaltrials/show/nct03718767https://clinicaltrials.gov/study/NCT03718767https://ascopubs.org/doi/10.1200/JCO.2023.41.16_suppl.e14043
66
MonoNCT04922723ACTIVE_NOT_RECRUITINGRadiation/​Temozolomide and Immunotherapy With Daratumumab to Improve Antitumor Efficacy in Glioblastoma (PRIDE)Phase 1/2Newly DiagnosedAnyWest Virginia UniversitySonikpreet Aulakh, MDsonikpreet.aulakh@hsc.wvu.eduhttps://findmecure.com/clinicaltrials/show/nct04922723https://clinicaltrials.gov/study/NCT04922723https://ascopubs.org/doi/10.1200/JCO.2018.36.15_suppl.e14030
67
MonoNCT04214392ACTIVE_NOT_RECRUITINGChimeric Antigen Receptor (CAR) T Cells With a Chlorotoxin Tumor-Targeting Domain for the Treatment of MMP2+ Recurrent or Progressive GlioblastomaPhase 1RecurrentAnyCity of Hope Medical CenterBehnam Badiebbadie@coh.orgMust be confirmed by COH Clinical Pathology to be MMP2 positive tumorhttps://findmecure.com/clinicaltrials/show/nct04214392https://clinicaltrials.gov/study/NCT04214392https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7500824/
68
MonoNCT04817254COMPLETEDAssociation of Peripheral Blood Immunologic Response to Therapeutic Response to Adjuvant Treatment With Immune Checkpoint Inhibition (ICI) in Patients With Newly Diagnosed Glioblastoma or GliosarcomaPhase 2Newly DiagnosedAnyNational Cancer Institute (NCI)NCI NOB Referral Groupncinobreferrals@mail.nih.govTreatment is nivolumab plus ipilimumab (i.e., dual checkpoint inhibitors)https://findmecure.com/clinicaltrials/show/nct04817254https://clinicaltrials.gov/study/NCT04817254
69
MonoNCT03382977TERMINATEDStudy to Evaluate Safety, Tolerability, and Optimal Dose of Candidate GBM Vaccine VBI-1901 in Recurrent GBM SubjectsPhase 1/2RecurrentAnyVBI Vaccines Inc.Bebi Yassin-Rajkumar, MSBYassin-Rajkumar@vbivaccines.comTwo study arms: VBI-1901 versus SOC (carmustine or lomustine)https://findmecure.com/clinicaltrials/show/nct03382977https://clinicaltrials.gov/study/NCT03382977https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10766231/
70
MonoNCT05139056SUSPENDEDMultiple Doses of Neural Stem Cell Virotherapy (NSC-CRAd-S-pk7) for the Treatment of Recurrent High-Grade GliomasPhase 1RecurrentAnyCity of Hope Medical CenterJana Portnowjportnow@coh.orghttps://findmecure.com/clinicaltrials/show/nct05139056https://clinicaltrials.gov/study/NCT05139056https://pubmed.ncbi.nlm.nih.gov/34214495/